Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Objectives Evaluate long‐term effectiveness and tolerability of brivaracetam in clinical
practice in patients with focal epilepsy. Materials and Methods This was a multicenter …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …

Abstract Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL)
belong to the dibenzazepine family of antiepileptic drugs and are all thought to primarily act …

Abstract The Euro-Esli study was an exploratory pooled analysis of data from 14 European
clinical practice studies, which was conducted to audit the real-world effectiveness, safety …

Background: Antiseizure medications can have negative effects on plasma lipid levels.
Objectives: To evaluate plasma lipid changes in patients with newly diagnosed focal …

Introduction: Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED)
approved for adjunctive treatment in adults, children, and adolescents with focal-onset …

Purpose To assess the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in
patients transitioning from carbamazepine or oxcarbazepine to ESL in clinical practice, by …

Aim The aim of the study was to evaluate the effectiveness and tolerability of
eslicarbazepine acetate (ESL) when used as monotherapy for 1 year or more in routine …

Objectives To assess the effectiveness and safety/tolerability of eslicarbazepine acetate
(ESL) monotherapy in clinical practice in Europe. Materials and methods Euro‐Esli was a …